stage from late at inflection for point a we company commercial We're our exciting us an you today. journey joining Thank for Concert because to continue organization. development becoming
and a THRIVE-AAX from is untapped trial The top best-in-class X today dollar data quarter EADV we late deuruxolitinib potential deuruxolitinib line the agents second additional deuruxolitinib. releasing position positive released to and significant onset treatment JAKX/X from we profile THRIVE-AAX, our These as deuruxolitinib regrowth inconsistent results our Congress clinical in and September past in first Phase the results by from satisfaction. weeks session doses in for In international secondary now best both the the placebo, Milan. clinically in this XXXX, degrees showed we studied that its will XX presented data THRIVE-AA alopecia met for and at deuterated After clinical during at largely early that of compared potentially areata. of trials and new THRIVE-AAX forward, from name, high results August multibillion breaking endpoints areata disease. of the pivotal believe alopecia both news overall refer We inhibitor and has top of doses line to key a meaningful of both CTP-XXX, with effect trials, deuruxolitinib evaluated. primary market that Going scalp patient THRIVE-AAX a
us some we our in and with open over support and half XXXX for sizable giving of It's and data grow of three supporting able clinicians, in NDA to been years planned Importantly, awareness deuruxolitinib data have present to THRIVE-AA a to gratifying the of extension deuruxolitinib us experts now months share to the to excellent and in continue study, present results commercialization. experience ahead. the additional detailed patients the label in we'll the community database for safety filing within treatment participating treatment be dermatology and first future the
regrowth. more EADV very stringent news Building the and THRIVE-AAX were As a of the King breaking at session. scores, late during eyebrow a present prime the and regrowth of results Brett line top he on example, showcased have Congress the University SALT previously effect we measure on hair released XXXX Yale of happy to eyelash XX the results, Dr. deuruxolitinib the
to data, endpoint by the we As demonstrate believe efficacy continues primary measures. deuruxolitinib impressive these with SALT XX additional
additional data the parse analyses forward sharing we trials, community. to Phase X extensive look medical the from we with As the
data satisfaction. by THRIVE-AA which regrowth of effect both placebo highlight are hair high feel quantitative key onset secondary rapid these statistical two patient of attributes trials. King, in of Beyond deuruxolitinib, and versus important significant and Both Dr. showed into endpoints we results other the as plan it measurements key to described built analysis our were the
who Specifically, improve SALT level deuruxolitinib study. patients we weeks. change The significant study as onset the early we've in XX-week SALT statistically in as open the of changes weeks. course see scores, weeks to as THRIVE-AAX versus of significant completion at was as we study, effect previously, beyond early early SALT deuruxolitinib as the scores at relative the in XX described continue receive to in and eight the as the throughout in favoring as placebo extension and continue When improve XX four THRIVE-AAX look continue to legal
this from Congress stratified disease safety loss at both will THRIVE-AA will World which Australia, alopecia Hair THRIVE-AAX safety for King by effect in we additional deuruxolitinib Regarding data of believe we was the to by the duration is which profile look deuruxolitinib studies, month, suited present similar in the which of Dr. Later the and episode. trials observed a in X, Phase -- the of for the will treatment areata. that results at severity, look include Research hair well current
effective and of of our place data first Within is that an Phase time alopecia opportunity, only a worldwide, therapeutic large be potential forms the in large XXXX. Concert, than clearer areata to in that basis NDA patients X our are commercial plan had filing, autoimmune our prepare to some team we've trials millions addition a to important blockbuster that expect affects It's options offers a core compelling deuruxolitinib. and the NDA from beginning application. where of the We we treatment deuruxolitinib for emerge. The common that ever submit will market disease which for half to
of to or However, conducted up the work CMC wrapping course, there are and filing. we that several studies are supporting support have
execute In what let we're our accomplished to our underscore as a to have bringing that throughout program. quickly committed continue have and deuruxolitinib to of possible, proud I highly as they plan defined timelines team team and I'm we're consistently We has to headed. well our me that market as closing, have confidence where extremely will and forward, going every the
Let quarter discussion to financial third me the here and results. to Marc pause review turn our
